Moderna Price Targets Raised by Multiple Analysts in February 2026

Two financial services firms raised their price targets for Moderna (MRNA) on February 17, 2026, reflecting increased optimism for the biotechnology company. RBC Capital raised its price target from $25.00 to $30.00 USD while maintaining a 'Sector Perform' rating, marking a 20% increase. Evercore ISI Group raised its price target from $28.00 to $35.00 USD, a 25% increase, while maintaining an 'In-Line' rating.

The stock traded around $42.38 to $43.50 in mid-February 2026. Options trading activity showed a put/call ratio of 0.2, considerably lower than the usual 0.64 ratio. Call option interest surpassed puts, with 17,000 contracts exchanged. The implied volatility for Moderna was pegged at 82.57 and rising by 8.0 points, remaining in the upper range of its yearly trend. This increase indicates a potential daily price fluctuation of approximately $2.20.

Based on one-year price targets offered by 20 analysts, the average target price for Moderna is $41.01 with a high estimate of $135.00 and a low estimate of $12.00. The average target implies a downside of 4.53% to 5.73% from the current price. Based on the consensus recommendation from 25 brokerage firms, Moderna's average brokerage recommendation is currently 3.0, indicating 'Hold' status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Recent analyst activity has shown mixed signals. On January 7, 2026, UBS assumed coverage and lowered the price target from $40.00 to $34.00 USD, changing the rating from 'Buy' to 'Neutral'. On December 12, 2025, Jefferies initiated coverage with a 'Hold' rating, setting the price target at $30.00 USD. On December 12, 2025, Morgan Stanley maintained its 'Equal-Weight' rating and lowered the price target from $30.00 to $28.00 USD. On November 21, 2025, Leerink Partners maintained its 'Underperform' rating while raising the price target from $15.00 to $18.00 USD. On November 21, 2025, RBC Capital maintained its 'Sector Perform' rating but lowered the price target from $28.00 to $25.00 USD.

Moderna's financial metrics reveal significant challenges. Revenue for the trailing twelve months stands at $1.944 billion, with a three-year revenue growth rate of -41.3%. Margins are deeply negative, with an operating margin of -157.27% and a net margin of -141.51%. Balance sheet strength is indicated by a current ratio of 3.93 and a debt-to-equity ratio of 0.08. The price-to-sales ratio is 7.42. Warning signs include a low Piotroski F-Score of 3, indicating poor business operations, and insider selling activity with 24,357 shares sold over the past three months. The Altman Z-Score of 4.27 indicates strong financial health, while the Beneish M-Score of -2.51 suggests the company is unlikely to be a manipulator.

Institutional ownership is substantial at 70.28%, while insider ownership is 6.03%. The 14-day RSI of 53.99 indicates a neutral market sentiment. Volatility remains high, with a volatility measure of 63.11 and a beta of 1.06.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The company has a market capitalization of approximately $16.44 billion and operates within the healthcare sector, specifically in the biotechnology industry.